Targeting DDX3 with a small molecule inhibitor for lung cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Lung cancer is a leading global malignancy with limited treatment options.
• DEAD-box helicase 3 (DDX3) is overexpressed in lung cancer, correlating with poor patient survival.
• Targeting DDX3 presents a potential therapeutic strategy for lung cancer.

Purpose of the Study:

• To investigate the therapeutic potential of a novel small molecule inhibitor, RK-33, targeting DDX3 in lung cancer.
• To elucidate the mechanisms by which DDX3 inhibition affects cancer cell proliferation, survival, and DNA repair.

Main Methods:

• Design and synthesis of RK-33, a first-in-class DDX3 inhibitor.
• In vitro studies assessing RK-33's effects on cell cycle, apoptosis, and radiation sensitivity in DDX3-overexpressing lung cancer cells.
• In vivo studies using mouse models of lung cancer to evaluate RK-33 in combination with radiation therapy.
• Mechanistic studies involving shRNA and RK-33 to analyze Wnt signaling and DNA repair pathways (non-homologous end joining).

Main Results:

• RK-33 effectively inhibited DDX3 activity, leading to G1 cell cycle arrest and apoptosis in cancer cells.
• RK-33 demonstrated radiosensitizing effects in DDX3-overexpressing cells.
• Combination therapy of RK-33 and radiation induced significant tumor regression in preclinical lung cancer models.
• DDX3 inhibition disrupted the DDX3-β-catenin axis in Wnt signaling and impaired non-homologous end joining DNA repair.

Conclusions:

• RK-33 is a potent inhibitor of DDX3 with significant anti-cancer activity in lung cancer models.
• DDX3 inhibition offers a promising therapeutic avenue by impacting cell cycle, apoptosis, Wnt signaling, and DNA repair.
• Further development of DDX3 inhibitors like RK-33 is warranted for lung cancer treatment.